Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model
Authors:
- Raul GomezRGRaul Gomez
- Miguel Gonzalez-IzquierdoMGMiguel Gonzalez-Izquierdo
- Ralf C. ZimmermannRZRalf C. Zimmermann
- Edurne Novella-MaestreENEdurne Novella-Maestre
- Isabel Alonso-MurielIAIsabel Alonso-Muriel
- Jose Sanchez-CriadoJSJose Sanchez-Criado
- Jose RemohiJRJose Remohi
- Carlos SimonCSCarlos Simon
- Antonio PellicerAPAntonio Pellicer
- 1 November 2006
- journal article
- Published by The Endocrine Society in Endocrinology
- Vol. 147 (11) , 5400-5411
Abstract
No specific treatment is available for ovarian hyperstimulation syndrome (OHSS), the most important complication in infertile women treated with gonadotropins. OHSS is caused by increased vascular permeability (VP) through ovarian hypersecretion of vascular endothelial growth factor (VEGF)-activating VEGF receptor 2 (VEGFR-2). We previously demonstrated in an OHSS rodent model that increased VP was prevented by inactivating VEGFR-2 with a receptor antagonist (SU5416). However, due to its toxicity (thromboembolism) and disruption of VEGFR-2-dependent angiogenic processes critical for pregnancy, this kind of compound cannot be used clinically to prevent OHSS. Dopamine receptor 2 (Dp-r2) agonists, used in the treatment of human hyperprolactinemia including pregnancy, inhibit VEGFR-2-dependent VP and angiogenesis when administered at high doses in animal cancer models. To test whether VEGFR-2-dependent VP and angiogenesis could be segregated in a dose-dependent fashion with the Dp-r2 agonist cabergoline, a well-established OHSS rat model supplemented with prolactin was used. A 100 μg/kg low-dose Dp-r2 agonist cabergoline reversed VEGFR-2-dependent VP without affecting luteal angiogenesis through partial inhibition of ovarian VEGFR-2 phosphorylation levels. No luteolytic effects (serum progesterone levels and luteal apoptosis unaffected) were observed. Cabergoline administration also did not affect VEGF/VEGFR-2 ovarian mRNA levels. Results in the animal model and the safe clinical profile of Dp-r2 agonists encouraged us to administer cabergoline to oocyte donors at high risk for developing the syndrome. Prophylactic administration of cabergoline (5–10 μg/kg·d) decreased the occurrence of OHSS from 65% (controls) to 25% (treatment). Therefore, a specific, safe treatment for OHSS is now available.Keywords
This publication has 75 references indexed in Scilit:
- Ablation of Peripheral Dopaminergic Nerves Stimulates Malignant Tumor Growth by Inducing Vascular Permeability Factor/Vascular Endothelial Growth Factor-Mediated AngiogenesisCancer Research, 2004
- The Presence of a Single Tyrosine Residue at the Carboxyl Domain of Vascular Endothelial Growth Factor Receptor-2/FLK-1 Regulates Its Autophosphorylation and Activation of Signaling MoleculesJournal of Biological Chemistry, 2002
- Comparison of the Effects of Cabergoline and Bromocriptine on Prolactin Levels in Hyperprolactinemic Patients.Internal Medicine, 2001
- Interactions of FLT-1 and KDR with Phospholipase C γ: Identification of the Phosphotyrosine Binding SitesBiochemical and Biophysical Research Communications, 1997
- RU486-Treated Rats Show Endocrine and Morphological Responses to Therapies Analogous to Responses of Women with Polycystic Ovary Syndrome Treated with Similar Therapies1Biology of Reproduction, 1996
- Pregnancy outcome after treatment with the ergot derivative, cabergolineReproductive Toxicology, 1996
- A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of LactationDrug Safety, 1996
- Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndromeThe Lancet, 1994
- Effects of Chronic Bromocriptine Treatment of an Estrone-Induced, Prolactin-Secreting Rat Pituitary AdenomaHormone Research, 1985
- Induction of 20α-hydroxysteroid dehydrogenase in rat corpora lutea by pharmacological blockade of pituitary prolactin secretionBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1969